Results 111 to 120 of about 45,377 (263)

Cannabis use and cannabis use disorder among older adults in the USA

Addiction, EarlyView.
Abstract Background and aims Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
Benjamin H. Han, Evan L. Eschliman, Joseph J. Palamar, Mireia Triguero Roura, Pia M. Mauro   +4 more
wiley   +1 more source

A decade of cannabis‐related hospital admissions in Victoria, Australia: A retrospective observational study

Addiction, EarlyView.
Abstract Background and aims Over the past decade, there has been increased lifetime use of illicit and medical cannabis, underscoring the need to examine public health impacts. This includes reports of increased cannabis‐related psychosis. In this context, this study aimed to determine all cannabis‐related hospital admissions in Victoria, Australia ...
Myfanwy Graham, Janneke Berecki‐Gisolf, Jane Hayman, Adrian Carter, Shalini Arunogiri, Suzanne Nielsen   +5 more
wiley   +1 more source

Changes in the transition from cannabis use to use disorder by decade of first use: Findings from the Australian National Mental Health and Wellbeing surveys

Addiction, EarlyView.
Abstract Background and aims As cannabis becomes increasingly accessible and products more potent, it is critical that we understand how this may impact the risk of transitioning from cannabis use to cannabis use disorder (CUD). We aimed to examine whether the risk and speed of transition from cannabis use to CUD differ by decade of first cannabis use.
Jack Wilson, Siobhan O'Dean, Christina Marel, Olivia Dobson, Matthew Sunderland, Steph Kershaw, Tara Gückel, Emma Krogh Devine, Tim Slade, Maree Teesson, Emily Stockings   +10 more
wiley   +1 more source

Identification and quantification of Δ‐9‐tetrahydrocannabinol and the synthetic cannabinoid MDMB‐4en‐PINACA in edible products seized by United Kingdom police in 2024

Addiction, EarlyView.
Abstract Background and aims Cannabis edible products are increasingly being sold on the illicit market around the world. Use of these products, typically labelled as containing Δ‐9‐tetrahydrocannabinol (THC), has been linked to adverse health effects, particularly amongst adolescents.
Matthew Gardner, Kathryn Proctor, Martha Old, Gyles Cozier, Oliver Sutcliffe, Jennifer Scott, Stephen M. Husbands, Tom P. Freeman, Peter Sunderland, Christopher R. Pudney   +9 more
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Addiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke, Johan Duflou, Agata Chrzanowska, Michael Farrell, Julia Lappin, Amy Peacock   +5 more
wiley   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Stability of ∆9-THC, 11-OH-THC and THC-COOH in Whole Blood in Presence of Formalin Solution

Journal of Analytical Toxicology, 2019
Aude, Eibel, Alice, Ameline, Jean-Sébastien, Raul, Pascal, Kintz   +3 more
openaire   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Thermal Conversion of Cannabinoids in Hemp Flower: Decarboxylation Kinetics and Potential Accumulation of Δ⁹‑Tetrahydrocannabinol. [PDF]

ACS Omega
Carrera DÁ, Mazurov AA, Latino DARS, George GM, Katsir L.   +4 more
europepmc   +1 more source